Liquidia Corporation logo LQDA - Liquidia Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
1
BUY 5
HOLD 0
SELL 1
STRONG
SELL
0
| PRICE TARGET: $63.00 DETAILS
HIGH: $67.00
LOW: $60.00
MEDIAN: $62.00
CONSENSUS: $63.00
UPSIDE: 3.31%

About Liquidia Corporation (https://www.liquidia.com)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Key Executives

NAME TITLE DOB SALARY
Roger A. Jeffs Chief Executive Officer & Director 1962 $2,121,744 USD
Michael Kaseta Chief Operating Officer & Chief Financial Officer 1976 $1,406,072 USD
Russell Schundler General Counsel & Corporate Secretary 1976 $1,171,097 USD
Rajeev Saggar Chief Medical Officer 1975 $1,166,848 USD
Scott Moomaw Chief Commercial Officer 1971 $980,961 USD
Beth-Anne Lang Senior Vice President of Global Regulatory Affairs
Christian Perez Font Senior Vice President, Chief Compliance Officer & Associate General Counsel
Dana Boyle Chief Accounting Officer 1985
Frank Bartolini Senior Vice President of Market Access
Gareth Gwyn Senior Vice President of Medical Affairs
Harold Alterson Senior Vice President of Quality
Jason Adair Chief Business Officer 1972
Matt Snow Senior Vice President of Sales
Michael Hunter Senior Vice President of Manufacturing Operations
Michael Post Senior Vice President of Marketing
Sarah Krepp SPHR Chief Human Resources Officer 1982

Company Peers

Peer analysis pending, check back in 1-2 minutes.